Introduction
The incidence of head and neck squamous cell carcinoma (HNSCC) in the western countries is approximately 120,000 patients 1 with approximately two-thirds of locoregionally submit your manuscript | www.dovepress.com
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Fayette et al advanced head and neck squamous cell carcinoma (LAHNSCC). Radiotherapy (RT) is a major pillar of treatment for LAHNSCC and is given as exclusive treatment or as adjuvant treatment after surgery. 2 For both adjuvant and exclusive treatment, chemoradiotherapy (CT-RT) with every 3 weeks cisplatin (q3w) at a dose of 100 mg/m² at days 1, 22, and 43 gives better overall survival (OS) than RT alone in several Phase III studies. [3] [4] [5] [6] It is confirmed in a large meta-analysis on 50 concomitant trials: the hazard ratio (HR) for OS was 0.81 (95% confidence interval [CI] [0.78-0.86], P0.0001) with an absolute benefit of 6.5% at 5 years in favor of CT-RT vs RT alone. 7 However, this increased OS was associated with an increased toxicity. For example, in an adjuvant study, the rate of grade 3/4 acute toxicities was increased from 34% with RT alone to 77% (P0.001) with CT-RT. 5 The late toxicity increased in the q3w schedule compared with the q1w schedule. Although only few data are published, a small study reported 47% of grade 3/4 late toxicities in the RT group against 82% (P=0.02) in the CT-RT group. 8 Indeed, the major requirement now is to decrease the toxicity associated with CT-RT without altering its efficacy. The three major tumor types for which radiation is potentialized by cisplatin are HNSCC, undifferentiated nasopharyngeal carcinoma (UCNT), and cervical cancers. For the two later localizations, weekly cisplatin (q1w) at the dose of 40 mg/ m 2 is the standard potentiation, even though no direct comparison was done with the q3w cisplatin. [9] [10] [11] [12] [13] [14] For UCNT, q1w cisplatin was feasible and seemed to be less toxic than q3w cisplatin. In terms of OS, a Phase III study demonstrated that RT-CT with q1w cisplatin compared to RT alone increased the 5 years OS from 59% (95% CI [50. 9- 9 and an absolute benefit of 6.5% at 5 years, respectively. 10 This benefit of 6.5% was similar to the benefit obtained by using q3w cisplatin in LAHNSCC. 7 Although no study demonstrated equivalence or noninferiority of weekly cisplatin compared to q3w cisplatin as potentiation for RT in head and neck cancer, the q1w schedule is largely used due to its lower toxicity as it is expected to have efficacy similar to that of the q3w schedule.
This study was designed to assess to what extent should q1w cisplatin replace the q3w schedule, to obtain similar survival results and better tolerability, and can be a basis for a randomized study.
Patients and methods retrieval procedure and selection of patient records
The data of all patients without metastasis with histologically confirmed LAHNSCC, irradiated with concurrent cisplatin (q1w or q3w) in our institution (Centre Léon Bérard, Lyon, France) between January 2004 and December 2008, were retrospectively reviewed. Patients received an exclusive RT or RT after surgery and/or induction chemotherapy.
Collection of patients' data was in rules with CNIL (Commission nationale de l'informatique et des libertés, French authority to protect the use of patients' data) and the confidentiality of the patients was preserved. This study was authorized by the ethics committee of the Centre Léon Bérard (Lyon, France).
Treatment
RT was delivered over a 7-week period using conventional fractionation (total dose, 60-70 Gy). Generally, RT starts 3-7 weeks after completion of chemotherapy or surgery. Q3w chemotherapy was planned to be delivered (100 mg/m 2 ) at days 1, 22, and 43 from the start of RT, whereas q1w cisplatin (40 mg/m 2 ) was planned to be delivered each week during the RT treatment. Patients were hospitalized 24-48 hours for q3w cisplatin administration, and an intravenous hyperhydration with 2 L/m 2 of 0.9% NaCl or 5% glucose (with 2 g/L KCl and 4 g/L NaCl) was given; in the q1w schedule, cisplatin was administered ambulatory with 1L intravenous hydration and devices for orally hydration at home. All patients received adequate antiemetic prophylaxis. The choice between q1w and q3w was left to the appraisal of the radiotherapist, which was largely subjective and needed a multivariate analysis, but the considerations were age, weight loss before radiation, creatinine clearance, performance status, and the use of induction chemotherapy. In practice, such radiotherapists use systematically q1w cisplatin, and other radiotherapists use q3w cisplatin. In case of poor CT-RT tolerability, the patients could be re-hospitalized or receive a nasogastric intubation.
statistical analysis
Study population was first described and data were compared between CT-RT groups (q1w vs q3w) using Student's t-test or nonparametrical Wilcoxon's test for continuous data and Pearson's chi-square test or Fisher's exact test for categorical data.
Then, OS and progression-free survival (PFS) analyses were performed. Because of the presence of many comorbidities in the patients with LAHNSCC, time to progression (TTP) study was also done to compare the CT-RT schedules (q1w and q3w).
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Q3w cisplatin remains the standard potentiation of radiotherapy for lahnscc OS was defined as the time from RT onset to the date of death (due to any cause) or date of last follow-up (for censored patients); PFS as the time from RT onset to the date of recurrence (local or metastatic) or death (due to any cause) or date of last follow-up (for censored patients); and TTP as the time from RT onset to the date of recurrence (local or metastatic) or death due to cancer or date of last follow-up (for censored patients). Survival distributions were estimated by Kaplan-Meier method and compared between CT-RT groups using the log-rank test. Prognostic effect of CT-RT group was explored using proportional hazard Cox model. As the purpose of this study was to estimate the potential effect of the CT-RT modality (q1w or q3w) on survival, the strategy of modeling implemented consisted in adjusting this variable on the unbalanced covariates revealed by the descriptive analysis, as they may be the confounding factors. All interactions between the type of CT-RT and these variables were also tested and incorporated into the multivariate model (if significant at 5% level).
All analyses were performed using the SAS software version 9.3 (SAS institute Inc, Cary, NC, USA).
Results
Patients' characteristics
Between January 2004 and December 2008, 165 patients without metastasis with LAHNSCC received chemoradiation with q1w cisplatin and 97 with q3w cisplatin in a single institution (Centre Léon Bérard) and were retrospectively included in our study.
The characteristics of patients and tumors are summarized in Table 1 . About half of the patients (47.9%) had oropharyngeal cancer and 38.3% received induction chemotherapy (33.9% of patients were treated with q1w CT-RT and 45.8% with q3w CT-RT) without significant difference at 5% level (P=0.057).
Six characteristics were significantly different between patients treated with q1w and q3w CT-RT: median age at treatment initiation (58. 
Toxicity of the chemoradiation
Data about toxicities of chemoradiation and their management are summarized in Tables 2 and 3 , respectively. (Figure 2 ).
Since patients with LAHNSCC have a lot of comorbidities, the TTP should also be a good parameter to compare the two schedules. Among the 125 deceased patients, 88 died of cancer whereas 37 died of comorbidities. The 88 patients who died of cancer had previously relapsed. The 3 years and the 5 years TTP rates for all the patients were 64.0% (95% CI [57. 7- (Figure 3) .
In order to assess the relationship between survival rates (OS, PFS, and TTP) and CT-RT group, by taking into account the differences between the two groups revealed by the comparative description of study population, a multivariate Cox model was built to estimate CT-RT group effect by adjusting on the following potential confounding factors: age at RT initiation, alcohol consumption, prior neoadjuvant Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
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Q3w cisplatin remains the standard potentiation of radiotherapy for lahnscc In the same way, the tendency of a deleterious effect of q1w on survival was not confirmed by PFS or TTP multivariate analyses. Results regarding the analysis done on the subgroup of patients who did not receive induction chemotherapy (n=161) are similar.
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Fayette et al Figure 3 Time to progression according to the type of chemotherapy. Abbreviations: q1w, once weekly; q3w, every 3 weeks; pts, patients.
Discussion
Our study is consistent with the previously published monoarm studies which demonstrated that weekly cisplatin concurrent with RT is well tolerated. [15] [16] [17] [18] [19] [20] [21] [22] In this study, the largest published to date, weekly cisplatin is significantly better tolerated than q3w cisplatin. It is confirmed by only one comparative study, 23 whereas three did not show any difference [24] [25] [26] and one found 3qw schedule to be less toxic. 27 Even if weekly cisplatin is probably less toxic than q3w administration, which is presently the standard treatment, our survival results are consistent with the idea that the q3w administration should remain the standard. At the first look the trend according to which the OS (and PFS and TTP) would be better on patients treated by q3w schedule to the detriment of those weekly treated (q1w) was quite strong according to the Kaplan-Meier curves. However, this tendency (out of favor of the experimental arm [q1w schedule]) was not confirmed (at 5% level) according to the results of the multivariate Cox models.
As this study is both monocentric and retrospective, these results may just reflect one's own practice and may suffer from a selection bias that can affect the constitution of the two CT-RT groups, since the clinical reality of a patient guides the indication of CT-RT (q3w or q1w). A plausible hypothesis would be that q3w treatment plan is priority intended for patients expected to support such boost of chemotherapy and let q1w to weaker patients.
In fact, as the descriptive analysis illustrates, the patients who received the q1w chemotherapy presented more deleterious baseline characteristics than the patients treated every 3 weeks (q3w): older and slimmer patients before RT onset, more alcohol consumers, more renal failure before RT. On the contrary, patients of the q3w arm presented more advanced tumors (stage IV) and node involvement at diagnosis. These differences constitutes a major limitation that prevents us from demonstrating in a formal way the potential substitutability of the weekly chemotherapy to the chemotherapy administered every 3 weeks. For that purpose, a randomized and comparative trial, to insure the comparability between the groups (which is lacking in this study), would be necessary.
When our results were compared to those of the literature, we noticed that the absolute survival difference between the two CT-RT groups of approximately 10%, at least found here (5 years OS, PFS, and TTP rates), was similar to that observed in a meta-analysis which assessed the benefit of chemoradiation against RT alone, 7 suggesting that q1w cisplatin could be of limited interest. But, as said, the two groups in our study are not well balanced and no definitive conclusion could be drawn on the basis of our results. There is no convincing comparative study in the literature to assess the equivalence of q1w. Indeed, the five published studies dedicated to that subject did not demonstrate any difference in terms of efficacy, but they included only approximately 50 [24] [25] [26] [27] or 94 23 patients.
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On the other hand, mono-arm studies were conducted and results were compared with historical data of 3qw cisplatin: five studies seemed to be in favor of q1w, 15, 16, [18] [19] [20] one was with deleterious effects, 21 and one was without benefit. 17 In this last study, which included 103 patients retrospectively, there was no cumulative effect of the dose of cisplatin, suggesting again that weekly cisplatin could be of little interest when compared with RT alone. The only comparative study that demonstrated significant benefit of weekly cisplatin added to RT vs RT alone included only 83 patients, 22 which is not sufficient to assess a new standard. Hence, for eligible patients the q3w schedule should remain the gold standard. In order to decrease the toxicity of q3w cisplatin, we launched a program in our institution to perfuse patients at home for 5 days after chemotherapy with 1 L of NaCl at the night.
On the contrary to HNSCC, the potentiation of radiation by weekly cisplatin at the dose of 40 mg/m 2 is a validated standard for squamous cervical cancer [12] [13] [14] and undifferentiated carcinoma of the nasopharynx (UCNT). 11 For UCNT, other studies demonstrated the benefit of the 3qw cisplatin 28 or high-dose scheme, 29 but no direct comparative studies are available to attest the superiority of one schedule or their equivalence.
Since no large trial validated the superiority of weekly cisplatin potentiation compared with RT alone, it remains unclear as to which type of potentiation should be proposed to patients ineligible for 3qw cisplatin. Weekly carboplatin was not validated. 29, 30 The combination of carboplatin and fluorouracil brings positive results but is also toxic and probably not indicated for patients ineligible to q3w cisplatin. 4 Cetuximab should be considered since it is superior to exclusive RT alone. 31 But it did not demonstrate significant benefit for patients older than 65 years, the most numerous candidates for potentiation other than q3w. For eligible patients, no direct study compared exclusive RT potentiated by q3w cisplatin or cetuximab. Presently, the only indirect monocentric study suggests that cetuximab is not as efficient, but this small retrospective study cannot bring definitive response. 32 For adjuvant RT, cetuximab has no authorization. After induction chemotherapy, cetuximab could be as efficient as q3w cisplatin for early local control, 33 but no potentiation (cisplatin or cetuximab) demonstrated any superiority to RT alone.
Conclusion
To conclude, the temptation of potentiation of RT for LAHN-SCC with q1w cisplatin, in order to decrease the toxicity and increase the future quality of life, should not be recommended outside clinical trials, since our results do not suggest any strong survival improvement. That encourages us to consider the use of weekly cisplatin with very high precaution for the moment and to powerfully explore q3w alternatives, thanks to the large comparative clinical trials. In routine practice, if patients are fit, q3w cisplatin should remain the standard potentiation of RT for LAHNSCC.
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